Industry, Cancer Groups Draft Blueprint For PD-1 Companion Dx Approvals

Drug and test firms want to standardize FDA's companion diagnostic assessments for the high-profile new class of PD-1/PD-LI immunotherapy cancer drugs, an issue discussed at a recent FDA/cancer groups meeting.